RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the
Company" or "RegeneRx") reported that data showing that Thymosin beta 4
(Tβ4) "provides both neuroprotection and neurorestoration after
traumatic brain injury (TBI)," was published in the current (May 2012)
edition of the Journal of Neurosurgery, 116:1081-1092.
As reported in the epub edition of the journal, the aims of the study
were to test if Tβ4 treatment initiated 6 hours after traumatic brain
injury in rats reduces brain damage and improves functional recovery.
According to the research team, "Compared with saline administration,
Tβ4 treatment initiated 6 hours postinjury significantly improved
sensorimotor functional recovery and spatial learning, reduced cortical
lesion volume and hippocampal cell loss, and enhanced cell proliferation
and neurogenesis in the injured hippocampus. Thymosin β4 treatment
initiated 6 hours postinjury provides both neuroprotection and
neurorestoration after TBI, indicating that Tβ4 has promising
therapeutic potential in patients with TBI."
"These results are extremely encouraging and are consistent with results
of Tβ4 administration in other Central nervous system injuries, as well
as in cardiovascular injury models. Moreover, the reduction of brain
damage, improved motor function, and regeneration of injured brain
tissue, when Tβ4 is administered 6 hours after TBI, suggest that it
could potentially be useful for the treatment of brain traumas seen in
the military, the workplace and in contact sports," stated Dr. Allan
Goldstein, Professor and Chairman Emeritus, Department of Biochemistry
and Molecular Biology, The George Washington University School of
Medicine, Washington, D.C. Dr. Goldstein is also chairman of and chief
scientific advisor to RegeneRx.